Repurposing Bazedoxifene for Cancer Therapeutics: It is Much more than a SERM
Tomas Koltai · Asian Oncology Research Journal · 2020
Bazedoxifene (BDF) is a selective estrogen receptor modulator (SERM) that has been approved by the FDA for the treatment of post-menopausal osteoporosis in association with conjugated estrogens. BDF shares many of the pharmacological effects of tamoxifen with the advantage of not...
Open access
Research Article